176 related articles for article (PubMed ID: 37196218)
1. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.
Krumm N; Khasnavis NS; Radke M; Banda K; Davies HR; Pennil C; McLean K; Paulson VA; Konnick EQ; Johnson WC; Huff G; Nik-Zainal S; Swisher EM; Lockwood CM; Salipante SJ
JCO Precis Oncol; 2023 May; 7():e2200720. PubMed ID: 37196218
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
3. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
4. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
5. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
6. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
8. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
9. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.
Liu Y; Li Y; Zhang MZ; Chen D; Leng Y; Wang J; Han BW; Wang J
Cancer Genet; 2023 Apr; 272-273():35-40. PubMed ID: 36758499
[TBL] [Abstract][Full Text] [Related]
14. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
[TBL] [Abstract][Full Text] [Related]
15. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
[TBL] [Abstract][Full Text] [Related]
16. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract][Full Text] [Related]
17. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
19. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
20. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]